Waisence Q23 Qing Re Capsule
Waisence Q23 Qing Re Capsule : Product registered in Malaysia. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.
NPRA, Malaysian pharmaceutical products register, retrieved 27 October 2026.
Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0
The foreign register category does not determine the regulatory category of the product in France.
French and European references for recognised ingredients
- Conditions légales
Glycyrrhiza uralensis Fisch.: La portion journalière recommandée ne doit pas conduire à une ingestion d'acide glycyrrhizinique supérieure à 100 mg. L'étiquetage doit comporter un avertissement avec la teneur suivante: "Ne pas utiliser pendant plus de 6 semaines sans avis médical." L'étiquetage doit comporter un avertissement déconseillant l'emploi chez les enfants.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Rheum palmatum L.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes et une mention déconseillant l'usage prolongé.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.
Published composition
| Published ingredient | Published text and quantity | Identified nutrient or substance |
|---|---|---|
| Lonicera japonica | Lonicera japonica[37.5 mg,450 mg] | Not identified |
| Forsythia suspensa | Forsythia suspensa[37.5 mg,450 mg] | Not identified |
| Platycodon grandiflorum | Platycodon grandiflorum[28.2 mg,450 mg] | Not identified |
| Inula japonica | Inula japonica[28.2 mg,450 mg] | Not identified |
| Achyranthes bidentata | Achyranthes bidentata[28.2 mg,450 mg] | Not identified |
| Rheum palmatum | Rheum palmatum[25 mg,450 mg] | Not identified |
| Chrysanthemum indicum | Chrysanthemum indicum[25 mg,450 mg] | Not identified |
| Angelica dahurica | Angelica dahurica[23.4 mg,450 mg] | Not identified |
| Schizonepeta tenuifolia | Schizonepeta tenuifolia[18.7 mg,450 mg] | Not identified |
| Ligusticum chuanxiong | Ligusticum chuanxiong[18.7 mg,450 mg] | Not identified |
| Gardenia jasminoides | Gardenia jasminoides[18.7 mg,450 mg] | Not identified |
| Glycyrrhiza uralensis | Glycyrrhiza uralensis[18.7 mg,450 mg] | Not identified |
| Gypsum fibrosum | Gypsum fibrosum[18.7 mg,450 mg] | Not identified |
| Saposhnikovia divaricata | Saposhnikovia divaricata[14.1 mg,450 mg] | Not identified |
| Mentha haplocalyx | Mentha haplocalyx[12.5 mg,450 mg] | Not identified |
| Arctium lappa | Arctium lappa[12.5 mg,450 mg] | Not identified |
| Scrophularia ningpoensis | Scrophularia ningpoensis[12.5 mg,450 mg] | Not identified |
| Isatis indigotica | Isatis indigotica[12.5 mg,450 mg] | Not identified |
| Elephantopus scaber | Elephantopus scaber[12.5 mg,450 mg] | Not identified |
| Scutellaria baicalensis | Scutellaria baicalensis[12.5 mg,450 mg] | Not identified |
| Bupleurum chinense | Bupleurum chinense[12.5 mg,450 mg] | Not identified |
| Taraxacum mongolicum | Taraxacum mongolicum[12.5 mg,450 mg] | Not identified |
| Vitex trifolia | Vitex trifolia[9.4 mg,450 mg] | Not identified |
The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.
Product record
- Registration number
- MAL26076060TC
- Type
- Natural product
- Published status
- PRODUCT APPROVED
- Licence holder
- WAISENCE SDN BHD
- Manufacturer
- WAN YEEN TRADING SDN. BHD.
- Registration period starting
- 2026-07-07
- Published validity end
- 2031-07-07
Original register data
View published fields and their variants
- Active ingredients
- Lonicera japonica[37.5 mg,450 mg],Forsythia suspensa[37.5 mg,450 mg],Platycodon grandiflorum[28.2 mg,450 mg],Inula japonica[28.2 mg,450 mg],Achyranthes bidentata[28.2 mg,450 mg],Rheum palmatum[25 mg,450 mg],Chrysanthemum indicum[25 mg,450 mg],Angelica dahurica[23.4 mg,450 mg],Schizonepeta tenuifolia[18.7 mg,450 mg],Ligusticum chuanxiong[18.7 mg,450 mg],Gardenia jasminoides[18.7 mg,450 mg],Glycyrrhiza uralensis[18.7 mg,450 mg],Gypsum fibrosum[18.7 mg,450 mg],Saposhnikovia divaricata[14.1 mg,450 mg],Mentha haplocalyx[12.5 mg,450 mg],Arctium lappa[12.5 mg,450 mg],Scrophularia ningpoensis[12.5 mg,450 mg],Isatis indigotica[12.5 mg,450 mg],Elephantopus scaber[12.5 mg,450 mg],Scutellaria baicalensis[12.5 mg,450 mg],Bupleurum chinense[12.5 mg,450 mg],Taraxacum mongolicum[12.5 mg,450 mg],Vitex trifolia[9.4 mg,450 mg]
- Valid until
- 2031-07-07
- Registration date
- 2026-07-07
- Published description
- NATURAL PRODUCT
- Licence holder
- WAISENCE SDN BHD
- Producer
- WAN YEEN TRADING SDN. BHD.
- Published name
- Waisence Q23 Qing Re Capsule
- Published reference
- 2026030521634T
- Registration number
- MAL26076060TC
- Published status
- PRODUCT APPROVED
Official source
View the official register, number MAL26076060TC
Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Glycyrrhiza uralensis
Read the warning, when it applies and the studies cited
DEGLYCYRRHIZINATED LICORICE Buccal
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 31 October 2025
Deglycyrrhizinated Licorice Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 31 January 2025
LICORICE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Gardner and McGuffin 2013).
Sources cited by Health Canada (1)
- Gardner Z, McGuffin M. editors. 2013. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press.
Condition of application: Cough relief.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if cough worsens or persists (for) more than 1 week (EMA 2012).
Sources cited by Health Canada (1)
- EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
Condition of application: Gastritis relief.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Condition of application: All products.
Do not use if you are pregnant (EMA 2012).
Sources cited by Health Canada (2)
- EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
- Gardner Z, McGuffin M. éditeurs. 2013. American Herbal Products Association's Botanical Safety Handbook, 2e édition. Boca Raton (FL): CRC Press.
Do not use if you have hypokalemia, high blood pressure, or a kidney, liver or cardiovascular disorder (EMA 2012; Brinker 2010; ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (4)
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (UK): British Herbal Medicine Association; 1992.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Do not use if you are taking heart medications, corticosteroids, stimulant laxatives, or other health products that may contribute electrolyte imbalance (Brinker 2010; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000).
Sources cited by Health Canada (4)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
- Arctium lappa
Read the warning, when it applies and the studies cited
Burdock - Arctium Lappa - Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Barnes et al. 2007).
Sources cited by Health Canada (2)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Contraindications
Do not use if you are pregnant (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Known adverse reactions
Condition of application: All products.
Stop use if hypersensitivity/allergy occurs (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Condition of application: All products except those making a diuretic claim.
When using this product diuretic effect may occur.
Health Canada monograph dated 19 December 2025
BURDOCK - ARCTIUM LAPPA - Topical
Cautions and warnings
For external use only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Barnes 2007).
Sources cited by Health Canada (2)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): Pharmaceutical Press; 2007.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
When using this product avoid contact with eyes and mucous membranes. If contact occurs, rinse thoroughly with water.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Waisence Q23 Qing Re Capsule”, https://compoatlas.com/en/supplements/malaysia/MAL26076060TC-waisence-q23-qing-re-capsule, updated 27 October 2026.